Tag: initial public offering

Miami, FL, June 17, 2026 (GLOBE NEWSWIRE) -- Collective Acquisition Corp. II (Nasdaq: CAIIU) (the “Company”) announced today that, commencing June 22, 2026, holders of the units issued in the Company’s initial public offering (the “Units”), each consisting of one Class A ordinary share of the Company (the “Class A Ordinary Shares”) and one-half of one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share at an exercise price of $11.50 per share, may elect to separately trade the Class A Ordinary Shares and Warrants included in the Units. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. The Class A Ordinary Shares and Warrants will trade on the Nasdaq Global Market under the symbols “CAII” and “CAIIW,” respectively. Units not separated will continue to trade on the Nasdaq Global Market under the symbol “CAIIU.”

Pursuant to the Market Abuse Regulation (EU) no. 596/2014, as amended, article 19, InstallatørGruppen A/S (“InstallatørGruppen”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in InstallatørGruppen and their closely associated persons in InstallatørGruppen’s shares.

Reporting of transactions made by persons discharging managerial responsibilities and their closely associated persons in InstallatørGruppen's shares

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31^st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of BitGo Holdings, Inc. (NYSE: BTGO): (i) Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with BitGo's January 22, 2026 initial public offering ("IPO"); and/or (ii) securities between January 22, 2026 and May 13, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026.

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Via Transportation, Inc. (NYSE: VIA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Via's initial public offering (the "IPO" or “Offering”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BitGo To Contact Him Directly To Discuss Their Options